<p>NAFLD n = 16; NASH n = 36; controls n = 50. Data are expressed as mean±SEM. AUC, area under the curve; c<sub>max</sub>, maximum plasma concentration. Multiple Mann-Whitney tests with Bonferroni-Holm adjustment of p-values for multiplicity of testing. P≤0.05, statistically significant difference; ns, not significant.</p
Background: Incretin therapy of type 2 diabetes patients is based on the fact that Incretin Effect i...
AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be present in some pe...
To investigate a possible role of an enteroinsular axis involvement in the pathogenesis of type 2 di...
<p><b>(A)</b> GLP-1 secretion in response to oGTT is significantly decreased in patients vs. control...
<p><b>(A)</b> GIP secretion in response to oGTT is not different in patients vs. controls. Patients ...
<p>Plasma glucose <b>(A, B)</b>, insulin <b>(C, D)</b> and glucagon <b>(E, F)</b> concentration curv...
Background. To validate a test for independent assessment of insulin secretion and insulin sensitivi...
OBJECTIVEdTo investigate glucose-dependent insulinotropic polypeptide (GIP) secretion in patients wi...
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)...
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)...
OBJECTIVE — The role of gut-derived incretin, glucose-dependent insulinotropic polypep-tide (also kn...
Background: Glucagon-like peptide-1 (GLP-1) is a powerful insulin secretagogue that is secreted in r...
Subjects with impaired glucose tolerance (IGT) are usually overweight and exhibit insulin resistance...
OBJECTIVE—To evaluate the glucose dependency of glucose-dependent insulinotropic polypeptide (GIP) e...
Exogenous glucagon-like peptide 1(GLP-1) bioactivity is preserved in type 2 diabetic patients, resul...
Background: Incretin therapy of type 2 diabetes patients is based on the fact that Incretin Effect i...
AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be present in some pe...
To investigate a possible role of an enteroinsular axis involvement in the pathogenesis of type 2 di...
<p><b>(A)</b> GLP-1 secretion in response to oGTT is significantly decreased in patients vs. control...
<p><b>(A)</b> GIP secretion in response to oGTT is not different in patients vs. controls. Patients ...
<p>Plasma glucose <b>(A, B)</b>, insulin <b>(C, D)</b> and glucagon <b>(E, F)</b> concentration curv...
Background. To validate a test for independent assessment of insulin secretion and insulin sensitivi...
OBJECTIVEdTo investigate glucose-dependent insulinotropic polypeptide (GIP) secretion in patients wi...
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)...
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)...
OBJECTIVE — The role of gut-derived incretin, glucose-dependent insulinotropic polypep-tide (also kn...
Background: Glucagon-like peptide-1 (GLP-1) is a powerful insulin secretagogue that is secreted in r...
Subjects with impaired glucose tolerance (IGT) are usually overweight and exhibit insulin resistance...
OBJECTIVE—To evaluate the glucose dependency of glucose-dependent insulinotropic polypeptide (GIP) e...
Exogenous glucagon-like peptide 1(GLP-1) bioactivity is preserved in type 2 diabetic patients, resul...
Background: Incretin therapy of type 2 diabetes patients is based on the fact that Incretin Effect i...
AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be present in some pe...
To investigate a possible role of an enteroinsular axis involvement in the pathogenesis of type 2 di...